Matson Evaluation of Drug Side-Effects (MEDS) profiles of selective serotonin reuptake inhibitors (SSRI) in adults with intellectual disability

Journal of Developmental and Physical Disabilities

Volumn 21, Issue 1, 2009, Pages 57-68

  Matson, Johnny L ^a   Rivet, Tessa T ^a   Fodstad, Jill C ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Adults; Antidepressants; Intellectual disabilities; Matson evaluation of drug side effects; Medications; MEDS; Psychotropic; SSRI

Indexed keywords

EID: 58849165219     PISSN: 1056263X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10882-008-9125-5     Document Type: Article

References (26)

1. C. D. Advokat E. A. Mayville J. L. Matson 2000 Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation Research in Developmental Disabilities 21 1 75 84
2. American Psychiatric Association [APA] (2000). Diagnostic and statistical manual of mental disorders (4th ed.) - text revision. Washington, D.C.: APA.
3. A. B. Biswas S. Bhaumik D. Branford 2001 Treatment-emergent behavioural side effects with selective serotonin re-uptake inhibitors in adults with learning disabilities Human Psychopharmacology: Clinical & Experimental 16 2 133 137
4. M. Garcia J. Matson 2008 Akathisia in adults with severe and profound intellectual disability: A psychometric study of the MEDS and ARMS Journal of Intellectual & Developmental Disability 33 2 171 176
5. D. Janowsky J. M. Davis 2005 Diagnosis and treatment of depression in patients with mental retardation Current Psychiatry Reports 7 6 421 428
6. J. L. Matson T. Dempsey 2008 Autism spectrum disorders: Pharmacotherapy for challenging behaviors Journal of Developmental and Physical Disabilities 20 2 175 191
7. J. L. Matson S. V. LoVullo 2008 A review of behavioral treatments for self-injurious behaviors of persons with autism spectrum disorders Behavior Modification 32 1 61 76
8. J. L. Matson C. J. Malone 2006 Validity of the sleep subscale of the Diagnostic Assessment for the Severely Handicapped-II (DASH-II) Research in Developmental Disabilities 27 1 85 92
9. Matson, J. L., & Neal, D. (2008). Psychotropic medication use for challenging behavior in persons with intellectual disabilities: an overview. Research in Developmental Disabilities. doi: 10.1016/j.ridd.2008.08.007.
10. J. L. Matson J. Wilkins 2008 Antipsychotic drugs for aggression in intellectual disability Lancet 371 9606 9 10
11. J. L. Matson E. A. Mayville J. Bielecki W. H. Barnes J. W. Bamburg C. S. Baglio 1998 Reliability of the Matson Evaluation of Drug Side Effects scale (MEDS) Research in Developmental Disabilities 19 6 501 506
12. J. L. Matson E. A. Mayville J. W. Bamburg C. S. Eckholdt 2001 An analysis of side-effect profiles of anti-seizure medications in persons with intellectual disability using the Matson Evaluation of Drug Side Effects (MEDS) Journal of Intellectual & Developmental Disability 26 4 283 295
13. J. L. Matson E. A. Mayville J. Bielecki Y. Smalls C. S. Eckholdt 2002 Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities Research in Developmental Disabilities 23 3 224 233
14. J. L. Matson M. L. González K. R. Smith C. Terlonge R. T. Thorson D. R. Dixon 2006 Assessing side effects of pharmacotherapy treatment of bipolar disorder: a 20-year review of the literature Research in Developmental Disabilities 27 5 467 500
15. Matson, J. L., Fodstad, J. C., & Rivet, T. T. (2008). The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS). Journal of Intellectual Developmental Disability.
16. J. L. Matson T. T. Rivet J. C. Fodstad 2008 Matson Evaluation of Drug Side-Effects (MEDS) profiles in adults with intellectual disability, tardive dyskinesia, and akathisia Journal of Developmental and Physical Disabilities 20 3 283 295
17. J. L. Matson T. T. Rivet J. C. Fodstad 2008 Psychometric properties and participant characteristics for persons with intellectual disability using the Matson Evaluation of Drug Side-effects (MEDS) Journal of Developmental and Physical Disabilities 20 3 243 255
18. R. Racusin K. Kovner-Kline B. H. King 1999 Selective serotonin reuptake inhibitors in intellectual disability Mental Retardation and Developmental Disabilities Research Reviews 5 4 264 269
19. C. A. W. Rijcken T. B. M. Monster J. R. B. J. Brouwers L. T. W. de Jong-van den Berg 2003 Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses? Journal of Clinical Psychopharmacology 23 6 657 659
20. A. N. Singh D. Kleynhans G. Barton 1998 Selective serotonin re-uptake inhibitors in the treatment of self-injurious behaviour in adults with mental retardation Human Psychopharmacology: Clinical & Experimental 13 4 267 270
21. S. K. Sohanpal S. Deb C. Thomas R. Soni L. Lenôtre G. Unwin 2007 The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review Journal of Intellectual Disability Research 51 10 750 765
22. Sparrow, S., Balla, D., & Cicchetti, D. V. (1984). The vineland adaptive behavior scales (survey form). Circle Pines, MN: American Guidance Service.
23. Tabachnick, B. G., & Fidell, L. S. (2007). Using multivariate statistics (5th ed.). Boston, MA: Allyn & Bacon/Pearson Education.
24. W. M. A. Verhoeven M. J. Veendrik-Meekes G. A. J. Jacobs Y. W. M. M. van den Berg S. Tuinier 2001 Citalopram in mentally retarded patients with depression: a long-term clinical investigation European Psychiatry 16 2 104 108
25. N. Weintrob D. Cohen Y. Klipper-Aurbach Z. Zadik Z. Dickerman 2002 Decreased growth during therapy with selective serotonin reuptake inhibitors Archives of Pediatrics & Adolescent Medicine 156 7 696 701
26. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. (2007). ATC/DDD Index 2007 Retrieved October 2007, from http://www.whocc.no/atcddd/.